Basaglar ® (insulin glargine) injection

100 units/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the indication for Basaglar® (insulin glargine)?

Basaglar is indicated to improve glycemic control in patients with diabetes.

US_cFAQ_BIV037_INDICATION
US_cFAQ_BIV037_INDICATION
en-US

Indication for Basaglar

Basaglar® (insulin glargine) 100 units/mL is a long-acting human insulin analog indicated to improve glycemic control in

  • adults and pediatric patients with type 1 diabetes, and
  • adults with type 2 diabetes.1

Basaglar is not recommended for the treatment of diabetic ketoacidosis.1

Reference

1Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Date of Last Review: April 19, 2022


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical